KẾT QUẢ HÓA TRỊ BỔ TRỢ TRƯỚC PHÁC ĐỒ 4AC-4T Ở BỆNH NHÂN UNG THƯ VÚ GIAI ĐOẠN TIẾN TRIỂN TẠI CHỖ

Abstract

Objectives:  Our study aims to describe the clinical and paraclinical characteristics of locally advanced breast cancer patients and evaluate the treatment outcomes and toxicity of neoadjuvant 4AC-4T regiments in this group. Patients and Methods: Retrospective, descriptive study on 52 patients with locally advancer breast cancer, were treated with neoadjuvant 4AC-4T regiment at National Cancer Hospital.  Results: The mean age was 49,6. The majority of them were in stage III (96,1%) while 3,9% patients were in stage IIB. 96,2% patients’s histology were invasive carcinoma of no special type (NST) and 73,1% was in grade II. After treatment, the complete clinical response rised from 5,8% (after 4 cycles of AC) to 26,9% (after 8 cycles of 4AC-4Docetacel). There was 1 patients progressed during 4 docetacel cycles. All of our patients were moved to modified radical mastectomy after neoadjuvant chemotherapy. The pathological complete response (pCR) rate was 28,8%. Most adverse events were manageable and tolerable. The most common toxicity was neutropenia with grade 1,2. Non hematological toxicities such as vomiting, fatigue and alopecia were also common and all of them were mild and moderate. Conclusion: In locally advanced breast cancer patients, 4AC-4Docetacel regiment in neoadjuvant setting is effective with tolerable tocxicity, therefore this regiment can be widely used as neoadjuvant chemotherapy prior to surgery in our country.